Helus Pharma Posts Q1 FY27 Results, Flags Q4 Topline Data for Depression Drug
HELP has more than doubled off its 52-week low of $3.76.
Summary
Helus Pharma reported first quarter fiscal 2027 results and provided a pipeline update. The company completed enrollment in the Phase 3 APPROACH study for HLP003 in major depressive disorder, with topline data expected in Q4 2026. A completed drug-drug interaction study showed a favorable profile, supporting HLP003 as a potential adjunctive treatment. The company also highlighted Phase 2 data for HLP004 in generalized anxiety disorder, showing a ~10-point improvement in Hamilton Anxiety Rating Scale at 6 weeks. This follows the appointment of Michael Halstead as CEO earlier this month and the $50 million offering closed in June. The stock is trading near its 52-week high, reflecting optimism around the upcoming data readout.
At the time of this announcement, HELP was trading at $11.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $11.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.